Trial Profile
A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Oleclumab (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SYNERGY; SYNERGY trial
- 23 Sep 2023 Results of Exploratory Biomarker Study from the Synergy Trial presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference
- 13 Jun 2023 Planned End Date changed from 1 Oct 2023 to 1 Apr 2025.
- 13 Jun 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Aug 2024.